BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The  company  B.S.I.A.  Ltd.  submitted  on  27  November  1996  an  application  for  Marketing 
Authorisation  to  the  European  Agency  for  the  Evaluation  of  Medicinal  Products  (EMEA)  for 
Pylobactell, through the centralised procedure. After agreement by the CPMP on 11 September 1997, 
this medicinal product was referred to Part B of the Annex to Council Regulation No (EC) 2309/93 of 
22 July 1993. 
The Rapporteur and Co-Rapporteur appointed by the CPMP were: 
Rapporteur: 
Prof. K Strandberg 
Co-Rapporteur:  Dr H Pittner 
Licensing status: 
The product was not licensed in any country inside or outside the EU at the time of submission of the 
application. 
2 
• 
• 
• 
• 
• 
• 
Steps taken for the assessment of the product 
The procedure started on 19 December 1996. 
The Rapporteur's first assessment report was circulated to all CPMP Members on 27 February 
1997. The Co-Rapporteur's first assessment report was circulated to all CPMP Members on 28 
February 1997. 
During the meeting on 15 April 1997 the CPMP agreed on the consolidated list of questions to 
be sent to the company. The final consolidated list of questions was sent to the Company on 16 
April 1997. 
The company submitted the responses to the consolidated list of questions on 14 August 1997. 
During  the  meeting  on  17-19  November  1997  the  CPMP,  in  the  light  of  the  overall  data 
submitted  and  the  scientific  discussion  within  the  Committee  issued  a  positive  opinion  for 
granting a Marketing Authorisation to B.S.I.A. Ltd. on 19 November 1997. 
The  CPMP  opinions  were  forwarded,  in  all  official  languages  of  the  European  Union,  to  the 
European Commission, which adopted the corresponding Decisions on 7 May 1998. 
1/1 
EMEA 2005 
 
 
 
 
 
 
 
 
 
